A Phase 4 interventional study of Live attenuated varicella vaccine in Varicella, sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd.. Status unknown at 3 sites in China. Open to participants aged Up to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-12.
Sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2022, is one of 14 in phase 4, and was the 28th registered.
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
Browse Chickenpox studies →5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:
SK Bioscience Co., Ltd. · Sites in Honduras, Philippines, Korea, Republic of and 1 more country
Ages 12 mo–12 yrs · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages up to 18
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 8–16 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 1–17 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in Vietnam
Ages 1–12 · Healthy volunteers
By country, each count listing its studies:
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: Up to 59 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 14 · Phase 4 14
First in 1998; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 37,920 is above the median of 475 across 149 interventional studies indexed under Chickenpox.
Median enrollment 404 across the 36 interventional studies. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sinovac (Dalian) Vaccine Technology Co., Ltd., one of the names counted as Sinovac Biotech Co., Ltd. Under that name alone:
Sinovac (Dalian) Vaccine Technology Co., Ltd. is the lead sponsor of 20 studies on the registry; 7 are open to participants now.
17 studies in Chickenpox by Sinovac Biotech Co., Ltd: 7 open now, 7 under way, 3 of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 17 studies in Chickenpox by Sinovac Biotech Co., Ltd, this one is the 2nd largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2022, is one of 8 in phase 4, and was the 7th registered.
Sinovac Biotech Co., Ltd’s Chickenpox studies by the year they started, since 2014.
1 of the studies testing Chickenpox Vaccine in Chickenpox that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07415252Phase 3SK Bioscience Co., Ltd.SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years | 2027-02-13 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sinovac Biotech Co., Ltd’s 17 in Chickenpox:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity and safety of a single dose of varicella vaccine in healthy children aged 1-6 years with different varicella immunization histories, to evaluate the antibody level of varicella-zoster virus in healthy people aged 0-59 years in Zhejiang Province.
This study is Phase Ⅳ clinical trial.The experimental vaccine manufactured by Sinovac(Dalian) Vaccine Technology Co., Ltd.This clinical trial consists of five parts,and A total of 37920 subjects will be enrolled.
Study 1,360 subjects including 120 subjects aged 1-3 years with no history of varicella vaccination ,240 subjects aged 4-6 years with a history of 1 dose of varicella vaccine will be enrolled to evaluate the immunogenicity and safety of varicella vaccine.All subjects will receive one dose of varicella vaccine.
Study 2,2530 subjects aged 0-59 years old will be enrolled and will be collected venous blood to detect varicella antibody and conduct investigation of varicella antibody level in healthy people.
Study 3,30000 subjects aged 1-12 years old will be enrolled to conduct safety observation study.All subjects will receive one dose of varicella vaccine and all adverse events of all subjects will be collected.
Study 4,5000 subjects aged 1-12 years old will be enrolled to conduct protective effect study of varicella vaccine after exposure.
Study 5,30 subjects aged 1-12 years old will be enrolled. Herpes fluid or pharyngeal swab samples of subjects will be collected to study the pathogenicity of varicella.
Unified Inclusion Criteria:
Special Inclusion Criteria for each study:
Inclusion criteria of the study population for immunogenicity and safety evaluation of varicella vaccine:
Inclusion criteria for investigation of varicella antibody level:
Inclusion criteria of the study population for safety evaluation of varicella vaccine mass vaccination:
Inclusion criteria of study population for protective effect of varicella vaccine after exposure:
Inclusion criteria of study population for etiological study on the pathogenic strains of varicella cases:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
360 subjects including 120 subjects aged 1-3 years with no history of varicella vaccination,240 subjects aged 4-6 years with a history of 1 dose of varicella vaccine will be enrolled to evaluate the immunogenicity and safety of varicella vaccine.All subjects will receive one dose of varicella vaccine.
Biological: Live attenuated varicella vaccine
Immunization levels will be monitored among 2530 subjects aged 0-59 years old and will be collected venous blood to detect varicella antibody.
Biological: Live attenuated varicella vaccine
30000 subjects aged 1-12 years old will be enrolled to conduct safety observation of mass vaccination of varicella vaccine.All subjects will receive one dose of varicella vaccine and all adverse events of all subjects will be collected.
Biological: Live attenuated varicella vaccine
5000 subjects aged 1-12 years old will be enrolled to conduct protective effect study of varicella vaccine after exposure.
Biological: Live attenuated varicella vaccine
30 varicella cases aged 1-12 years old from study 4 will be enrolled. Herpes fluid or pharyngeal swab samples of subjects will be collected to study the pathogenicity of varicella.
Biological: Live attenuated varicella vaccine
The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
GMT of varicella antibody in children aged 1-6 years
GMT of varicella antibody at 30 days after vaccination of varicella vaccine in children aged 1-6 years.
Time frame: 30 days after vaccination
GMT of varicella antibody in healthy people aged 0-59 years
GMT of varicella antibody at 30 days after vaccination in different age groups of healthy people aged 0-59 years.
Time frame: 30 days after vaccination
Seroconversion rates of varicella antibody in children aged 1-6 years
Seroconversion rates of varicella antibody at 30 days after vaccination of varicella vaccine in children aged 1-6 years.
Time frame: 30 days after vaccination
GMI of varicella antibody in children aged 1-6 years
GMI of varicella antibody at 30 days after vaccination of varicella vaccine in children aged 1-6 years.
Time frame: 30 days after vaccination
Incidence of adverse reactions at 24 hours after vaccination
Incidence of adverse reactions at 24 hours after vaccination of varicella vaccine in children aged 1-6 years
Time frame: 24 hours after vaccination
Incidence of adverse reactions at 3 days after vaccination
Incidence of adverse reactions at 3 days after vaccination of varicella vaccine in children aged 1-6 years
Time frame: 3 days after vaccination
Incidence of adverse reactions at 14 days after vaccination
Incidence of adverse reactions at 14 days after vaccination of varicella vaccine in children aged 1-6 years.
Time frame: 14 days after vaccination
Incidence of adverse reactions at 30 days after vaccination
Incidence of adverse reactions at 30 days after vaccination of varicella vaccine in children aged 1-6 years.
Time frame: 30 days after vaccination
Incidence of adverse reactions at 14 days after mass vaccination
Incidence of adverse reactions at 14 days after mass vaccination of varicella vaccine in children aged 1-12 years
Time frame: 14 days after mass vaccination
Incidence of adverse reactions at 30 days after mass vaccination
Incidence of adverse reactions at 30 days after mass vaccination of varicella vaccine in children aged 1-12 years
Time frame: 30 days after mass vaccination
seropositive rates of varicella antibody
Seropositive rates of varicella antibody at 30 days after vaccination in all age groups of healthy people.
Time frame: 30 days after vaccination
Started Jul 2022 (actual). Primary completion is estimated for Mar 2023, 7 months after the start.
Of 14 phase 4 interventional studies under Chickenpox, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's planned 7 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine
Sinovac (Dalian) Vaccine Technology Co., Ltd. →